1. Introduction {#sec1}
===============

Generally, sulfonamide drugs are well-known bacteriostatic antibiotics exhibiting significant activities against different bacterial strains.^[@ref1]^ Additionally, sulfonamides showed diverse pharmacological actions such as antidiabetic,^[@ref2]^ anticancer,^[@ref3],[@ref4]^ and antiviral potencies.^[@ref5]^ They are known to compete with *p*-aminobenzoic acid (*p*ABA) in binding to the active site of dihydropteroate synthase (DHPS) enzyme as a result of their comparable structures and thus inhibit the action of the enzyme. DHPS is involved in the folate synthesis through the catalysis of the reaction of 6-hydroxymethyl-7,8-dihydropterin-pyrophosphate with *p*ABA to afford the folate intermediate 7,8-dihydropteroate (DHF).^[@ref6]^ Thereafter, DHF is transformed to tetrahydrofolic acid (THF) through the action of the dihydrofolate reductase (DHFR) enzyme. Inhibiting the action of either DHPS or DHFR enzymes would eventually prevent the biosynthesis of THF required for the synthesis of purines and pyrimidine and would eventually lead to the death of the bacterial cell itself.^[@ref7]^ It is well-documented that many bacterial and fungi strains have developed a considerable resistance against several commercial drugs bearing a sulfonamide group.^[@ref8],[@ref9]^ Clinically speaking, the presence of the *p*ABA/sulfonamide binding site close to the protein surface through flexible protein loops that are amenable and tolerant to mutations was the main drive toward this bacterial resistance. Inasmuch, several research works have focused on DHFR as a viable target for enzyme inhibition through the action of different antimicrobial and anticancer agents because the enzyme is essential for both purine and thymidylate syntheses as well as the folate metabolism in cell proliferation. In the case of bacterial infections, both trimethoprim (TMP) and pyrimethamine drugs compete with the pteridine moiety of DHF in binding with the DHFR enzyme and resulting in enzyme inhibition. This is because both drugs possess a pyrimidine ring with two amino groups that are responsible for binding to the amino acids within the pterin pocket.^[@ref10],[@ref11]^ Combination of DHPS and DHFR inhibitors has proven to increase the therapeutic efficacy.^[@ref12]^ For example, it is known that sulfonamides have very little antiprotozoal action when used alone. However, combination of sulfonamides with TMP created synergistic effects. To elaborate more, the drugs separately have been shown to be bacteriostatic, while a combination of both is bactericidal. However, this combination is usually administered in the case of complicated urinary tract infections and *Pneumocystis carinii* infections in immune-compromised patients. Interestingly, the treatment is available orally for community acquired methicillin resistant *Staphylococcus aureus* (MRSA).^[@ref13]^

Furthermore, 2-pyridone derivatives are interesting heterocyclic scaffolds because of their various pharmacological properties.^[@ref14]^ Many medications based on 2-pyridone skeletons are used in the treatment of congestive heart failure^[@ref15]^ and bacterial infections caused by negative gram bacteria.^[@ref16],[@ref17]^ Extensive studies have been conducted to develop new forms of antibacterial,^[@ref18]^ antivirals,^[@ref19]^ antifungals,^[@ref20]^ antitumor,^[@ref21]^ and anti-inflammatory^[@ref22]^ agents that are based on 2-pyridone structures. Interestingly, 2-pyridone ring incorporating the sulfonamide moiety showed significant impact on the inhibition of the cellar wall of different types of bacteria, as was recently demonstrated.^[@ref23],[@ref24]^ Moreover, *N*-sulfonamide 2-pyridone derivatives have exhibited good antimicrobial activity against a variety of antimicrobial strains.^[@ref25],[@ref26]^

Development of drug resistance by different bacterial strains against both sulfonamide drugs and TMP^[@ref27]^ has encouraged us to design new compounds containing the sulfonamide group as DHPS inhibitors that are bonded to the six-membered ring such as pyridine substituted with the amino/hydroxyl group at the 6-position to inhibit DHFR, as shown in [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}. Based on our experience in the synthesis of novel compounds containing benzothiazoles, pyridines, and sulfonamide moieties,^[@ref28]−[@ref33]^ new compounds of *N*-sulfonamide 2-pyridones incorporating the benzothiazole moiety were envisaged and synthesized via the reaction of novel benzothiazol sulfonylhydrazide with ketene dithioacetal derivatives. To evaluate the antimicrobial potency of the new compounds, antimicrobial assessment, minimum inhibitory concentration (MIC), cytotoxicity, and enzyme inhibition of DHPS and DHFR as well as docking study of the most potent compounds were carried out.

![Design strategy and general structures of newly synthesized antimicrobial DHPS and DHFR inhibitors.](ao0c00280_0001){#fig1}

2. Results and Discussions {#sec2}
==========================

2.1. Chemistry {#sec2.1}
--------------

Various derivatives of *N*-sulfonamide 2-pyridones incorporating the benzothiazole moiety were synthesized starting with novel *N*′-(2-(benzo\[*d*\]thiazol-2-yl)acetyl)arylsulfonohydrazide compounds **3a,b**. The latter compounds were produced via the reaction of 2-(benzo\[*d*\]thiazol-2-yl)acetohydrazide **1** with arylsulfonyl chloride **2** in pyridine at room temperature, as shown in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}. To confirm the proposed structure of the newly synthesized sulfonyl hydrazide compound **3b**, an X-ray single crystal structure was ascertained, as shown in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}.^[@ref34]^

![X-ray single crystal structure of the title compound **3b** "Reproduced with permission of the International Union of Crystallography under the open-access licence".^[@ref34]^](ao0c00280_0002){#fig2}

![Synthesis of *N*-(3-(Benzo\[*d*\]thiazol-2-yl)-5-cyano-4-(methylthio)-2-oxopyridin-1(2*H*)-yl)arylsulfonamide](ao0c00280_0008){#sch1}

The reaction of *N*′-(2-(benzo\[*d*\]thiazol-2-yl)acetyl)arylsulfonohydrazides **3a,b** with ketene dithioacetals was exploited further to provide a general approach for the synthesis of 4-methylthio 2-pyridones **5a--d** and **9a--f**. We studied the reactivity of the CH~2~ group of compounds **3a,b** toward different derivatives of *S*,*S* ketene dithioacetals such as 2-(bis(methylthio)methylene)malononitrile **4a**, ethyl 2-cyano-3,3-bis(methylthio)acrylate **4b,** and 2-cyano-3,3-bis(methylthio)-*N*-arylacrylamide **6a--c** compounds, as shown in [Schemes [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"} and [2](#sch2){ref-type="scheme"}.

![Synthesis of 2-Amino-5-(benzo\[*d*\]thiazol-2-yl)-4-(methylthio)-6-oxo-*N*-aryl-1-(arylsulfonamido)-1,6-dihydropyridine-3-carboxamide](ao0c00280_0009){#sch2}

Reacting *N*′-(2-(benzo\[*d*\]thiazol-2-yl)acetyl)arylsulfonohydrazides **3a,b** with either 2-(bis(methylthio)methylene)malononitrile **4a** or ethyl 2-cyano-3,3-bis(methylthio)acrylate **4b** in dry dimethylformamide (DMF) containing pulverized potassium hydroxide produced compounds **5a,b** and **5c,d**, respectively, in good yield, [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}.

The structures of *N*-arylsulfonamide 2-pyridones **5a--d** were assigned based on their spectral data (FT-IR, ^1^H NMR, and ^13^C NMR) and elemental analyses. The IR spectra clearly revealed that both **5a** and **5b** compounds had NH~2~ groups as evident by the absorption bands at ν 3410--3296 cm^--1^ range, while those of compounds **5c** and **5d** showed a broad band at ν 3427 and 3431 cm^--1^ range, respectively, corresponding to the OH groups. According to ^1^H NMR of **5a--d**, the appearance of a singlet signal at a range of δ 2.31--2.59 ppm confirmed the presence of SCH~3~ protons. Additionally, in the case of compounds **5a** and **5b**, a broad signal at δ 7.50 and 7.63 ppm, respectively, confirmed the presence of NH~2~ groups, while in the case of compounds **5c** and **5d**, a singlet signal at δ 9.45 and 9.24 ppm, respectively, confirmed the presence of the OH group. Moreover, ^1^H NMR of compounds **5a--d** showed four distinctive signals corresponding to the four protons of benzothiazole ring. These signals are two triplet signals at the range of δ 7.32--7.68 ppm and two doublet signals at the range of δ 7.90--8.09 ppm with each signal representing a single proton. Furthermore, ^13^C NMR of **5a** showed a signal at δ 25 ppm for the SCH~3~ group and a signal at δ 117 ppm for the CN group.

To expand on the above findings, reactions involving alternative derivatives of *S*,*S* ketene dithioacetal compounds, namely, N-substituted bis(methylthiomethylene)(cyano)acetamide derivatives **6a--c**, were investigated. The reactions of **6a--c** with compounds **3a,b** in dry 1,4-dioxane containing a catalytic amount of potassium hydroxide afforded *N*-(4-methylthio-6-oxopyridin-1-yl)arylsulfonamides **9a--f**, whose structures were confirmed by analytical and spectral data, as shown in [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}. IR spectra of compounds **9a--f** showed a characteristic broad band at the range of ν 3413--3268 cm^--1^ corresponding to NH~2~ and NH groups. The ^1^H NMR spectrum of **9e**, as an example, revealed the presence of both NH~2~ group as a broad signal at δ 7.50 ppm and NHSO~2~ and CONH groups as two singlet signals at δ 10.35 and 11.46 ppm, respectively. The ^13^C NMR spectrum of **9f** confirmed the presence of CH~3~ and SCH~3~ at δ 19.5 and 21.4 ppm, respectively, and the OCH~3~ group at δ 55.1 ppm.

A possible mechanism for the formation of compounds **5a--d** and **9a--f** starts with the Michael addition of the active methylene carbon atom of compounds **3a,b** to the double bond of the *S*,*S* ketene dithioacetal compounds **4a,b** and **6a--c**, followed by the elimination of CH~3~SH and subsequent intramolecular cyclization resulting from the addition of a NH~2~ proton to either the cyano group to form compounds **5a,b** and **9a--f** or the carbonyl group to form compounds **5c** and **5d**, as shown in [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}.

Finally, upon heating *N*-arylsulfonamide 2-pyridones **5a,b** with hydrazine hydrate in a mixture of methanol/DMF (50:50), 1*H*-pyrazolo\[4,3-*c*\]pyrid-2-ones **11a,b** were successfully synthesized. Elemental analysis and spectral data confirmed the proposed structures of **11a,b**, as shown in [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}. The disappearance of the CN signal in both IR and ^13^C NMR spectra and the singlet signal of SCH~3~ at ^1^H NMR as well as the presence of the additional NH~2~ group at δ 5.57 confirmed the transformation of pyrido-2-ones **5a,b** to pyrazolopyrid-2-ones **11a,b**. Plausibly, the reaction proceeded via the hydrazinolysis of **5a,b** through the removal of the methylthio group and a subsequent cyclization through the NH~2~ group attack on the cyano group in pyrid-2-one ring to finally afford pyrazolopyrid-2-ones **11a,b**.

![Synthesis of *N*-(3,4-Diamino-7-(benzo\[*d*\]thiazol-2-yl)-6-oxo-1*H*-pyrazolo\[4,3-*c*\]pyridin-5(6*H*)-yl)arylsulfonamide](ao0c00280_0010){#sch3}

2.2. Biological Evaluation {#sec2.2}
--------------------------

### 2.2.1. Antimicrobial {#sec2.2.1}

The newly synthesized compounds were examined for their *in vitro* antibacterial potency against three Gram −ve bacteria, namely, *Klebsiella pneumonia*, *Pseudomonas aeruginosa,* and *Escherichia coli*, as well as two Gram +ve bacteria, namely, *Streptococcus mutans* and *Staphylococcus aureus*. They were also evaluated for their antifungal potency against *Candida albicans* fungal strain. The agar-diffusion method was used to determine the preliminary antibacterial and antifungal potencies. Standard drugs such as Ampicillin, Gentamicin, and Nystatin were also used against Gram +ve bacterial, Gram −ve bacterial, and fungal strains, respectively. Sulfonamide antibiotics such as sulfadiazine (SD) have also been tested and compared for its antibacterial efficacy versus that of the newly synthesized compounds. The antimicrobial results were reported as the average diameter of inhibition zones of the microbial growth around the disks in mm ± SD, as summarized in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}. The MIC measurements were also determined for the most potent compounds **3b**, **5a**, **5b**, **11a,** and **11b** using twofold serial dilution method, and the results are also summarized in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}.

###### Antibacterial Inhibition Zone in mm ± Standard Deviation of Synthesized Compounds

               diameter of the inhibition zone (mm)                                                       
  ------------ -------------------------------------- ------------ ------------ ------------ ------------ ------------
  **3a**       −[a](#t1fn1){ref-type="table-fn"}      20.0 ± 3.0   −            −            −            −
  **3b**       17.3 ± 2.5                             32.0 ± 2.0   −            17.6 ± 2.5   10.6 ± 0.5   −
  **5a**       26.0 ± 0.5                             20.6 ± 1.0   −            −            17.6 ± 1.5   21.0 ± 1.0
  **5b**       21.3 ± 3.0                             25.6 ± 1.1   23.3 ± 0.5   30.3 ± 0.5   18.6 ± 1.0   −
  **5c**       23.3 ± 1.5                             27.3 ± 1.5   −            17.6 ± 1.5   −            −
  **5d**       −                                      18.2 ± 0.5   −            17.5 ± 2.0   −            −
  **9a**       −                                      −            −            31 ± 1.0     −            −
  **9b**       −                                      −            −            27.1 ± 0.2   −            −
  **9c**       14.8 ± 0.2                             29.2 ± 0.3   −            −            20.2 ± 1.0   −
  **9d**       −                                      −            −            26.8 ± 1.5   8.8 ± 1.0    28.0 ± 0.7
  **9e**       −                                      −            −            19.6 ± 1.0   −            −
  **9f**       −                                      29.6 ± 1.5   −            −            −            −
  **11a**      26.0 ± 0.5                             15.2 ± 0.5   −            35.2 ± 1.5   22.3 ± 0.5   21.0 ± 1.7
  **11b**      26.0 ± 1.0                             17.5 ± 0.5   −            25.2 ± 1.0   21.0 ± 1.0   −
  Gentamicin   25.0 ± 0.1                             32.0 ± 0.1   35.0 ± 0.1   NT           NT           NT
  Ampicillin   NT[b](#t1fn2){ref-type="table-fn"}     NT           NT           32.0 ± 0.5   22.0 ± 0.5   NT
  Nystatin     NT                                     NT           NT           NT           NT           28.0 ± 0.1
  SD           19.8 ± 0.4                             20.4 ± 0.9   24.0 ± 1.4   31.2 ± 2.1   16.3 ± 1.1   NA

No activity.

Not tested.

###### MIC of the Most Active Compounds **3b**, **5a**, **5b**, **11a,** and **11b**

                                  The MIC (μg/mL)                                       
  ------------------------------- ----------------- ------ ------ ------- ------- ----- ------------
                                                                                        Gentamicin
  *E. coli* (ATCC: 3008)          250               62.5   125    31.25   31.25   250   31.25
  *K. pneumonia* (ATCC: 4415)     1000              1000   1000   125     125     250   62.5
  *P. aeruginosa* (ATCC: 27853)   NT                NT     1000   NT      NT      250   125
                                                                                        Ampicillin
  *S. aureus* (ATCC: 6538)        1000              NT     250    31.25   500     500   62.5
  *S. mutans* (ATCC: 25175)       1000              1000   1000   1000    500     125   62.5
                                                                                        Nystatin
  *C. albicans* (ATCC: 10231)     NT                62.5   NT     125     NT      NT    31.25

As shown in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, all the synthesized compounds showed no apparent activity against *P. aeruginosa* except for compound **5b**. It is equally clear that the antibacterial activity of sulfonyl hydrazides **3a** showed some activities against a particular bacterial strain, *K. pneumonia*, while **3b** showed similar inhibition zone against *K. pneumonia* when compared to Gentamicin (inhibition zone 32.0 ± 2.0 mm, MIC, 250 μg/mL) while showing lower activities than those of the standard drugs against *E. coli*, *S. aureus,* and *S. mutans*.

It was also noticed that arylsulfonylamino-2-pyridone derivatives **5a--d** ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}) displayed considerable antibacterial and fungal activities. In some instances, these compounds exhibited similar or slightly lower activities than those of the corresponding standard drugs. In this series, it was clear that compound **5a** showed activities slightly higher than Gentamicin and, therefore, was marked as the most potent against *E. coli* (inhibition zone 26.0 ± 0.5 mm, MIC, 62.5 μg/mL), while compound **5b** was marked as the most potent agent against *S. aureus* (inhibition zone 30.3 ± 0.5 mm, MIC, 250 μg/mL). Additionally, compound **5c** revealed strong activity against *K. pneumonia* (inhibition zone 27.3 ± 1.5 mm) in comparison to that of other derivatives in this series. Interestingly, compound **5a** was shown to be the only compound in this series that exhibited some antifungal activity against *C. albicans* (inhibition zone 21.0 ± 1.0 mm, MIC, 62.5 μg/mL).

According to the antimicrobial results, compounds **9a--e** showed some activities against Gram +ve bacterial strains, while the two compounds **9c** and **9f** showed some activities against Gram −ve bacterial strains, and only one compound, **9d**, showed equal potency against *C. albicans* fungal strain (inhibition zone 28.0 ± 0.7 mm) as compared to that of the standard drug Nystatin (inhibition zone 28.0 ± 0.1 mm). As shown in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, both compounds **9c** and **9f** revealed slightly lower activities than Gentamicin against *K. pneumonia* (inhibition zone 29 mm). Furthermore, compound **9a** was the most active compound in this series against *S. aureus* (inhibition zone 31.0 ± 1.0 mm). Only one compound **9c** in this series revealed slightly lower activity than Ampicillin against *S. mutans* (inhibition zone 20.2 ± 1.0 mm).

Interestingly, transformation of pyrid-2-ones **5a,b** to 1*H*-pyrazolo\[4,3-*c*\]pyrid-2-ones **11a,b**, as shown in [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}, significantly improved its antibacterial activities to a greater extent. The main observation was the effect of compound **11a** on the three bacterial strains, namely, *S. aureus*, *E. coli,* and *S. mutans*. Quite remarkably, compound **11a** showed a higher antimicrobial activity against *S. aureus* (inhibition zone 35.2 ± 1.5 mm, MIC, 31.25 μg/mL) than that of Ampicillin (inhibition zone 32.0 ± 0.5 mm, MIC, 62.5 μg/mL) with much lower MIC value. Moreover, compound **11a** revealed higher activity (inhibition zone 26.0 ± 0.5 mm, MIC, 31.25 μg/mL) as compared to that of Gentamicin (inhibition zone 25.0 ± 0.1 mm, MIC, 31.25 μg/mL) against *E. coli*. On comparing the antifungal effect of the standard drug, Nystatin (inhibition zone 28.0 ± 0.1 mm, MIC, 31.25 μg/mL), with that of compound **11a**, the latter showed good activity against *C. albicans* (inhibition zone 21.0 ± 1.7 mm, MIC, 125 μg/mL). Furthermore, compound **11b** possessed higher potency (inhibition zone 26.0 ± 1 mm, MIC, 31.25 μg/mL) than Gentamicin (inhibition zone 25.0 ± 0.1 mm, MIC, 31.25 μg/mL) against *E. coli* and a comparable activity (inhibition zone 21.0 ± 1.0 mm, MIC, 500 μg/mL) to that of Ampicillin (inhibition zone 22.0 ± 0.5 mm, MIC, 62.5 μg/mL) against *S. mutans*.

Additionally, the antibacterial efficacy of the synthesized compounds as detailed above was also compared to that of the well-known standard drug, SD. It was noticed that some of the tested compounds showed superior activities to the standard drug against different bacterial strains. Both thiomethylpyridon-2-ones **5a--c** and 1*H*-pyrazolopyrid-2-ones, **11a** and **11b**, exhibited higher potency than that of SD (inhibition zone rang 19.8 ± 0.4 mm, MIC, 250 μg/mL) against *E. coli*. Sulfonyl hydrazides **3a** and **3b** and thiomethylpyridon-2-ones **5a--c** exhibited excellent activity against *K. pneumonia* as compared to SD (inhibition zone 20.4 ± 0.9 mm, MIC, 250 μg/mL). Remarkably, unlike all other compounds in the series, 1*H*-pyrazolopyrid-2-one, compound **11a** showed higher potency against *S. aureus* than SD (inhibition zone 31.2 ± 2.1 mm, MIC, 500 μg/mL), which demonstrates the remarkable overall potencies of this compound against various bacterial strains.

Although SD had no activity against *C. albicans*, some of newly synthesized compounds such as compounds **5a**, **9d**, and **11a** revealed some potency (inhibition zone rang 21--28 mm).

### 2.2.2. Structural--Activity Relationship {#sec2.2.2}

The results of the antimicrobial examination demonstrated the following assumptions about the structural--activity relationship (SAR). The physicochemical properties evaluated in terms of the partition coefficient, log *P*, of the synthesized compounds were performed using Molinspiration, [Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}. Compounds with log *P* values ranging from 0 to 5 are considered to be a good oral bioavailability.^[@ref35]^ The results indicated that all synthesized compounds are having log *P* values less than 5. In the case of sulfonyl hydrazides **3a** and **3b**, it was observed that compound **3b**, which have a methyl group at the para-position of the benzene sulfonamide moiety, is more active than **3a** against the tested bacterial strains. It is also noticed that the lipophilic character of compound **3b**, log *P* of 2.50, has increased as a result of the presence of a methyl group at the para position. The thiomethylpyridon-2-one derivatives, **5a--d**, showed a strong antimicrobial activity. In the case of Y = NH~2~, [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}, the substituted benzene sulfonamide moiety with the methyl group at the para-position caused **5b** to be more active than that with an unsaturated benzene sulfonamide, **5a**, against the tested microbial strains except for *E. coli* and *C. albicans*. However, in the case of Y = OH, the test revealed greater activity for **5c** versus that of **5d** against the Gram −ve bacteria such as *K. pneumonia* and *E. coli*. An evidence of how influential the Y group in this series of compounds is on its antimicrobial activity.

###### Calculated Lipophilic Character log *P* of the Synthesized Compounds

![](ao0c00280_0011){#GRAPHIC-d7e1717-autogenerated}

  compd no.   Y       Ar        Ar~1~      log *P*[a](#t3fn1){ref-type="table-fn"}
  ----------- ------- --------- ---------- -----------------------------------------
  **3a**      −       Ph        −          2.06
  **3b**      −       4-Me-Ph   −          2.50
  **5a**      NH~2~   Ph        −          3.27
  **5b**      NH~2~   4-Me-Ph   −          3.72
  **5c**      OH      Ph        −          3.57
  **5d**      OH      4-Me-Ph   −          4.02
  **9a**      NH~2~   Ph        Ph         4.41
  **9b**      NH~2~   4-Me-Ph   Ph         4.86
  **9c**      NH~2~   Ph        4-Me-Ph    4.86
  **9d**      NH~2~   4-Me-Ph   4-Me-Ph    5.30
  **9e**      NH~2~   Ph        4-MeO-Ph   4.46
  **9f**      NH~2~   4-Me-Ph   4-MeO-Ph   4.91
  **11a**     NH~2~   Ph        −          2.43
  **11b**     NH~2~   4-Me-Ph   −          2.87
  SD                                       --0.04

Calculations were performed using Molinspiration online property calculation toolkit (<http://www.molinspiration.com>). log *P*: logarithm of compound partition coefficient between *n*-octanol and water.

Interestingly, structure manipulation in terms of various substituents on both the benzene ring of the sulfonamide moiety and that of the anilide group, thiomethylpyridon-2-one derivatives **9a--f**, led to a corresponding variation in their antimicrobial activities. To relate the impact of the molecular structure on the antimicrobial activities of this series of derivatives, substituents on one moiety were varied while keeping the other moiety intact and vice versa. In the case of no substituents on the benzene ring of the anilide group, compounds **9a,b**, the antimicrobial effectiveness revealed that compound **9a**, unsubstituted benzene sulfonamide derivative, had a higher activity against *S. aureus* than that of compound **9b**, having a methyl group at the para-position of the benzene sulfonamide moiety. Similar antimicrobial activities were also observed for compounds **9c,d** with a methyl group at the benzene ring of the anilide group. In the case of a methoxy group on the benzene ring of the anilide group, compounds **9e,f**, the antimicrobial activities revealed that compound **9e**, unsubstituted benzene sulfonamide derivative, had no activity against *K. pneumonia,* while compound **9f** with a methyl group at the para-position of the benzene sulfonamide moiety had strong activity. Interestingly, the opposite behavior was observed when testing the two derivatives against *S. aureus*.

It is interesting here to note that 1*H*-pyrazolo\[4,3-*c*\]pyrid-2-ones **11a** and **11b** showed the strongest antimicrobial activity among all tested compounds and a good lipophilic character confirmed by log *P* values of 2.43 and 2.87, respectively, attributed to the fusion of the bioactive pyrazole moiety with the 2-pyridinone ring. It was also observed that compound **11a** with an unsubstituted benzene sulfonamide moiety had a higher potency than compound **11b** having a methyl group at the para-position of the benzene sulfonamide moiety against all tested bacterial strains except for *K. pneumonia*. Surprisingly, compound **11a** also showed good antifungal activity against *C. albicans,* while compound **11b** showed no potency.

In general, the presence of a methyl group at the para position of the benzene sulfonamide moiety has depressed the antimicrobial activities of *N*-arylsulfonamide 2-pyridones as compared to that of unsubstituted benzene sulfonamide moiety.

According to the aforementioned results of antimicrobial inhibition zones, MIC and log *P*, most of the newly synthesized compounds and in particular compounds **3b**, **5a**, **5b**, **11a**, and **11b** exhibited notable potency as antimicrobial agents, which prompted us to further study their cytotoxicity and inhibition activities against both DHPS and DHFR enzymes.

### 2.2.3. Cytotoxicity Assessment {#sec2.2.3}

To study the inhibition activities of compounds exhibiting the highest activities namely, compounds **3b**, **5a**, **5b**, **11a,** and **11b**, *in vitro* cytotoxicity was evaluated against HFB4 human dermal fibroblast cell line using MTT assay with SD as a reference drug. Plotting the cell viability percent against the concentration of test compounds was done to determine the human dermal cell line viability toward the specified compounds, [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}. Values of the IC~50~ of the examined compounds are summarized in [Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}.

![Percentage of cell viability determined for **3b**, **5a**, **5b**, **11a**, **11b,** and SD using the MTT assay.](ao0c00280_0003){#fig3}

###### Anti-proliferative Activities of **3b**, **5a**, **5b**, **11a**, **11b**, and SD against HFB4 Human Skin Normal Cell Line Using MTT Assay

  comp.     IC~50~ (μg/mL)[a](#t4fn1){ref-type="table-fn"}
  --------- ------------------------------------------------
  **3b**    164.76 ± 3.04
  **5a**    167.28 ± 21.83
  **5b**    145.73 ± 26.99
  **11a**   233.51 ± 20.73
  **11b**   295.14 ± 19.05
  SD        242.56 ± 46.12

The data are expressed as the mean ± SD of three independent experiments.

The IC~50~ values shown in the table for compounds **3b**, **5a**, **5b**, **11a,** and **11b** were found to be 164.76, 167.28, 145.73, 233.51, and 295.14 μg/mL, respectively. Interestingly, compounds **11a** and **11b** exhibited a high IC~50~ values, while compounds **3b**, **5a** and **5b** showed low values toward the human dermal cell line as compared to that of SD. The results indicate that compounds **11a** and **11b** demonstrated a lower toxicity toward HFB4 human dermal fibroblast cell than SD did, while compounds **3b**, **5a** and **5b** exhibited a higher toxicity.

### 2.2.4. DHPS and DHFR *in Vitro* Enzyme Assay {#sec2.2.4}

The *in vitro* growth inhibitory activity of the most potent compounds **3b**, **5a**, **5b**, **11a,** and **11b** was studied on both DHPS and DHFR enzymes using DHPS catalytic assay and DHFR inhibitor screening kit, respectively. For the purpose of comparison, SD and TMP were used as reference drugs for DHPS and DHFR, respectively. The concentration of the tested compounds that is required to inhibit 50% of the cell population (IC~50~) was determined and is shown in [Tables [5](#tbl5){ref-type="other"}](#tbl5){ref-type="other"}--[7](#tbl7){ref-type="other"}.

###### IC~50~ Values of the Compounds **3b**, **5a**, **5b**, **11a,** and **11b** on the DHPS and DHFR Enzymes Using SD and TMP as Reference Drugs

  compd no.   IC~50~[a](#t5fn1){ref-type="table-fn"} (DHPS, μg/mL)   IC~50~[a](#t5fn1){ref-type="table-fn"} (DHFR, μg/mL)
  ----------- ------------------------------------------------------ ------------------------------------------------------
  **3b**      6.90 ± 0.44                                            0.37 ± 0.009
  **5a**      14.65 ± 0.96                                           0.26 ± 0.009
  **5b**      13.15 ± 0.74                                           0.30 ± 0.011
  **11a**     2.76 ± 0.16                                            0.20 ± 0.007
  **11b**     10.46 ± 0.07                                           5.52 ± 0.070
  SD          2.05 ± 0.12                                            NT
  TMP         NT                                                     0.17 ± 0.005

The data are expressed as the mean ± SD of three independent experiments.

###### Inhibition Activity of Compounds **3b**, **5a**, **5b**, **11a**, **11b**, and SD at Different Concentrations on the DHPS Enzyme

  compd no.   100 (μg/mL), %   10 (μg/mL), %   1 (μg/mL), %   0.1 (μg/mL), %
  ----------- ---------------- --------------- -------------- ----------------
  **3b**      74.41            53.94           34.16          7.63
  **5a**      66.66            49.27           20.74          12.24
  **5b**      66.59            52.91           21.81          5.87
  **11a**     77.28            63.44           42.71          21.01
  **11b**     71.96            48.82           25.80          9.94
  SD          76.38            67.79           42.76          26.15

###### Inhibition Activity of Compounds **3b**, **5a**, **5b**, **11a**, **11b**, and TMP at Different Concentrations on the DHFR Enzyme

  compd no.   10 (μg/mL), %   1 (μg/mL), %   0.1 (μg/mL), %   0.01 (μg/mL), %
  ----------- --------------- -------------- ---------------- -----------------
  **3b**      81.47           60.91          33.38            17.89
  **5a**      75.89           57.27          41.84            29.97
  **5b**      79.44           64.97          37.44            19.80
  **11a**     71.81           66.96          44.13            29.59
  **11b**     60.08           31.25          19.26            12.37
  TMP         88.07           66.11          43.02            25.51

The resulting data were thus used to plot a dose response curves, as shown in [Figures [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}. All the IC~50~ values of the tested compounds were compared to that of the reference drugs (*p* \< 0.0001 for compounds **3b**, **5a**, **5b,** and **11b** and *p* \< 0.01 for compound **11a**).

![Inhibition efficacy of the compounds toward (A) DHPS enzyme, (B) DHFR enzyme. The data are expressed as means ± SD of three separate experiments. *p* values were determined using GraphPad Prism Software (Student's test). \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, and \*\*\*\**p* \< 0.0001 vs reference drugs.](ao0c00280_0004){#fig4}

![Survival percentage of (A) DHFR enzyme and (B) DHPS enzyme at different concentrations of the compounds.](ao0c00280_0005){#fig5}

It is clear from the tables that the formation of 4-methylthio 2-pyridones **5b** (IC~50~ = 13.15 μg/mL) as compared to its starting compound **3b** (IC~50~ = 6.90 μg/mL) had resulted in a decreased potency against DHPS. However, its activities against DHFR (IC~50~ = 0.30 μg/mL) as compared to its starting compound **3b** (IC~50~ = 0.37 μg/mL) had increased. Obviously, the presence of the methyl group at the para-position of the benzene sulfonamide moiety plays an important role on the IC~50~ values. This has caused the increase in the IC~50~ values of methylthio 2-pyridones **5b** as compared to the unsubstituted benzene sulfonamide moiety **5a** against DHFR, while the IC~50~ values of **5b** had decreased when compared to that of the unsubstituted benzene sulfonamide moiety **5a** against DHPS. It was also observed that the presence of a pyrazole moiety fused with a 2-pyridone ring has remarkably affected the potency of the compounds against DHPS. In the case of compound **11a**, which contained the pyrazole moiety and an unsubstituted benzene sulfonamide moiety, the IC~50~ value has dropped to 2.76 μg/mL, while in the case of compound **11b** which has a pyrazole moiety and a methyl group at the para-position of the benzene sulfonamide moiety, the IC~50~ value reached 10.46 μg/mL. The resulting data indicate that the presence of the unsubstituted benzene moiety in **11a** led to an increase in the activities of the compound toward DHPS when compared to the corresponding compound with a methyl group at the para-position of the benzene sulfonamide moiety **11b**. Similar observation was also found when the activities of both compounds, **11a** and **11b**, against DHFR enzyme was evaluated and compared. The results show clearly that compound **11a** had the lowest IC~50~ value among all tested compounds against both DHPS and DHFR enzymes. To ascertain the potency of this compound versus that of standard drugs, its IC~50~ value (IC~50~ = 2.76 μg/mL) was compared to that of SD (IC~50~ = 2.05 μg/mL) against DHPS enzyme. Similarly, the IC~50~ value (IC~50~ = 0.20 μg/mL) of compound **11a** was also compared to that of the TMP standard drug (IC~50~ = 0.17 μg/mL) against DHFR enzyme.

According to the inhibition results, DHPS was treated with the synthesized compounds and the reference drug, SD, at four different concentrations, 100, 10, 1, and 0.1 (μg/mL) to evaluate the IC~50~ of each one. It was noticed that compound **11a** was the only compound that showed 77.28 inhibition % which is similar to the inhibition % of SD, 76.38%, at a concentration of 100 μg/mL. However, the inhibition % of SD, 26.15%, at a concentration of 0.1 μg/mL, was higher than the inhibition % of compound **11a**, 21.01%. Although compound **11a** showed similar inhibition to SD at a higher concentration, it showed lower inhibition than SD at a lower concentration, which led to increasing the IC~50~ of compound **11a**. In contrary, the inhibition % of DHFR when treated by compound **11a** was 71.81%, which is lower than that of TMP, 88.07%, at a concentration of 10 μg/mL and higher inhibition values, 29.59%, than that of TMP, 25.51%, at the low concentration of 0.01 μg/mL.

According to the above mentioned data, it is clearly showed that compound **11a** exhibited the strongest growth inhibition among all other tested compounds **3b**, **5a**, **5b**, and **11b** against both DHPS and DHFR enzymes. More importantly, the IC~50~ values of compound **11a** were found to be quite comparable to those of the reference drugs SD and TMP against the DHPS and DHFR enzymes, respectively. Therefore, this observed superior dual effect of compound **11a** makes it potentially of high significance in the treatment of bacterial infections.

2.3. Docking Studies {#sec2.3}
--------------------

Based on the results of the antimicrobial activities and enzyme assay, docking simulation was performed to better understand the interaction of the most potent compound, **11a**, with the binding sites of DHPS and DHFR enzymes. Docking studies were carried out using a crystal structure of DHPS (PDB ID: 3TYE)^[@ref36]^ and DHFR (PDB ID: 3FRB),^[@ref10]^ separately obtained from the Protein Data Bank server ([www.pdb.org](www.pdb.org)).

First, the docking studies were validated by docking the cocrystallized ligands of DHPS and DHFR inside the active sites after their extraction from the respective receptors. The re-docking of the cocrystallized ligands (XTZ for 3TYE and TOP for 3FRB) were carried out by removing the bound ligands, XTZ and TOP, from the complex followed by its docking back into the binding sites, which yielded root mean square deviation (rmsd) values of 2.4 Å and 2.2 Å, respectively. The top ranked poses obtained from the MOE docking simulation were thus selected for the compound under study. [Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}A--D shows the 2D and 3D interaction diagrams of both the cocrystallized ligand XTZ and the synthesized inhibitor, **11a**, within the active site of DHPS, while [Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}A--D shows the 2D and 3D interaction diagrams of both the cocrystallized ligand TOP and the synthesized inhibitor, **11a**, within the active site of DHFR.

![Binding mode of both the ligand (XTZ) and compound **11a** inside DHPS active site (PDB ID: 3TYE) using MOE. (A) 2D interaction of the ligand with DHPS (B) 3D interaction of the ligand (brown) with DHPS (C) 2D interaction of **11a** with DHPS (D) 3D interaction of **11a** (green) with DHPS.](ao0c00280_0006){#fig6}

![Binding mode of both the ligand (TOP) and compound **11a** inside the DHFR active site (PDB ID: 3FRB) using MOE. (A) 2D interaction of the ligand with DHFR (B) 3D interaction of the ligand (brown) with DHFR (C) 2D interaction of **11a** with DHFR (D) 3D interaction of **11a** (green) with DHFR.](ao0c00280_0007){#fig7}

It is well known that DHPS has two binding pockets. One is *p*-amino benzoic acid binding pocket (*p*ABA-binding pocket) capable of binding a *p*-amino benzoic acid group. The other is pterin-binding pocket capable of binding a dihydropterin pyrophosphate group.^[@ref37]^ Five amino acid residues, Asn120, Asp184, Lys220, Arg254, and His256, are considered as the key amino acids for the binding to the pterin-binding pocket, while the three amino acid residues, Lys220, Ser218 and Phe189, are the essential amino acids for the binding to the *p*ABA-binding pocket of DHPS enzyme. Benzene-sulfonamide moieties are known to occupy the *p*ABA-binding pocket and thus preventing the key substrate (*p*ABA) from binding to it, a common observation for all sulfa drugs.^[@ref38]^

The docking results showed that the cocrystallized ligand XTZ has four hydrogen-bond acceptors with Asn120, Lys220, and Ser22, three hydrogen-bond donors with Asn120 and Asp184, and one arene--H interaction with Lye220 within the DHPS pockets. The binding energy of compound **11a** was determined from the docking study to be −6.6785 kcal/mol. It was also shown from the docking patterns of compound **11a** that it fits well inside both the DHPS pterin- and *p*ABA-binding pockets. As shown in [Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}, compound **11a** exhibited four hydrogen-bond acceptors. One hydrogen bond is formed between the nitrogen atom of the benzothiazole ring and the NH~2~ group of Lys220 amino acid with a bond length of 2.95 Å. Two hydrogen bonds are located between the oxygen atom of the pyridone ring and both the NH~2~ and NH groups of Arg254 amino acid with bond lengths of 3.47 and 3.61 Å, respectively. The fourth one is formed between the oxygen atom of the sulfonamide group and the NH~2~ group of Asn27 amino acid with a bond length of 3.28 Å. According to these results, compound **11a** is attached to the protein molecule not only through one hydrogen bond with Lys220 amino acid within the *p*ABA-binding pocket but also through three hydrogen bonds with Lys220 and Arg254 amino acids within the pterin-binding pocket. The advantage of binding the compound to the pterin site is that it can get around the most prevalent method of bacterial resistance, which takes place within the *p*ABA binding pocket.

The interaction of the cocrystallized ligand TOP with DHFR revealed that the two amino groups at the pyrimidine and benzene rings are often the sites of interaction. The benzene ring created arene--H interactions, while the two amino groups established hydrogen bond donors with Phe92, Leu5, and Asp27 amino acids. Concerning the docking study of the tested compound **11a**, it showed that this compound can fit into the DHFR pocket with two hydrogen bonds donors with Phe92 and Asp27 amino acids similar to that of the cocrystallized ligand TOP, with bond lengths of 3.24 and 3.38 Å, respectively. Additionally, compound **11a** exhibited the third hydrogen bond donor between NH of the pyrazole ring and Ser49 amino acid with a bond length of 3.00 Å. [Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"} illustrated that the arene--H interaction has occurred between the pyridone ring and Thr46 amino acid. The binding energy of compound **11a** scored −7.4515 kcal/mol.

These interactions with the amino acids inside the pockets have provided a major explanation for the basis of the inhibition effect of compound **11a** on both the DHPS and DHFR enzymes, which highlighted its strong potential as a valid dual inhibitor for both DHPS and DHFR enzymes.

3. Conclusions {#sec3}
==============

In this work, novel compounds of *N*-sulfonamide 2-pyridones incorporating the benzothiazole moiety were produced through the reaction of newly synthesized benzothiazol sulfonylhydrazide compounds with ketene dithioacetal derivatives. Spectral and elemental analyses were both utilized to confirm the structures of the synthesized compounds. The inhibition zones, MIC and log*P* have all been assessed through the evaluation of the antimicrobial activities of the newly synthesized compounds. It was determined from the study that the majority of the synthesized compounds and in particular compounds **3b**, **5a**, **5b**, **11a,** and **11b** exhibited a notable potency as antimicrobial agents. The cytotoxicity and inhibition activities against both DHPS and DHFR enzymes showed that compound **11a** displayed the strongest growth inhibition among all tested compounds **3b**, **5a**, **5b,** and **11b** against both DHPS and DHFR enzymes with IC~50~ values comparable to those of the reference drugs, SD and TMP. Docking simulation of the most potent compound, **11a**, showed strong interactions with the amino acids inside the binding pockets of both DHPS and DHFR enzymes, which explains its remarkable inhibition effect on both DHPS and DHFR enzymes. The superior dual effect of compound **11a** makes it potentially of high significance in the treatment of bacterial infections.

4. Experimental Section {#sec4}
=======================

4.1. Chemistry {#sec4.1}
--------------

Melting points were determined on a digital SMP3 melting point apparatus using open capillary tubes and are uncorrected. IR spectra were recorded on an FTIR plus 460 or pyeunicam SP-1000 spectrophotometer using KBr pellets. ^1^H NMR (400 MHz) and ^13^C NMR (100 MHz) were done in the Center of Drug Discovery Research and Development at Ain Shams University, and spectra were recorded on a Bruker ADVANCE (III) model ultra shield NMR spectrometer in DMSO-*d*~6~ as a solvent using tetramethylsilane as an internal standard, and chemical shifts are reported as δ ppm units. The elemental analyses were done at the microanalytical data unit at Cairo University and performed on a vario EI III Elemental CHNS analyzer. Progress of the reactions were monitored by TLC using aluminum sheet coated with silica gel MERCK 60F 254 and was visualized using a UV lamp. The reagents and solvents were purchased in commercially available grade purity.

### 4.1.1. General Procedure for the Synthesis of **3a,b** {#sec4.1.1}

A solution of arylsulfonyl chloride **2a,b** (0.015 mol) in pyridine (10 mL) was added gradually to a stirred solution of 2-(benzo\[*d*\]thiazol-2-yl)acetohydrazide **1** (0.01 mol) in pyridine (10 mL) at 0 °C. The reaction mixture was stirred at room temperature for 3 h (TLC control). After the reaction was completed, the mixture poured onto ice water with continues stirring and neutralized with 1 N HCl solution until the pH of the solution reached to 7. The formed precipitate was filtrated off, washed with water, and recrystallized from ethanol.

#### 4.1.1.1. *N*′-(2-(Benzo\[*d*\]thiazol-2-yl)acetyl)benzenesulfonohydrazide (**3a**) {#sec4.1.1.1}

It was obtained as a white solid; (EtOH), yield 87%, mp 208--210 °C; IR (KBr, cm^--1^) ν: 3441 (NH), 3083 (ArCH), 2926 (Aliph-H), 1672 (CO), 1525 (C=N), 1341, 1159 (O=S=O); ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 3.98 (s, 2H, CH~2~), 7.41--7.45 (m, 3H, Ar-H), 7.51 (t, *J* = 8 Hz, 1H, benzothiazole-H), 7.57 (t, *J* = 8 Hz, 1H, benzothiazole-H), 7.80--7.78 (m, 2H, Ar-H), 7.96 (d, *J* = 8 Hz, 1H, benzothiazole H), 8.06 (d, *J* = 8 Hz, 1H, benzothiazole H), 10.07 (s, 1H, NH), 10.55 (s, 1H, NH); ^13^C NMR (100 MHz, DMSO-*d*~6~): 39.0 (CH~2~), 122.5, 122.7, 125.5, 126.5, 128.0, 129.2, 133.4, 135.8, 139.3, 152.6, 164.6, 166.5 (Ar-C); Anal. Calcd for C~15~H~13~N~3~O~3~S~2~ (347.41): C %, 51.86; H %, 3.77; N %, 12.10. Found: C %, 51.88; H %, 3.73; N %, 12.14.

#### 4.1.1.2. *N*′-(2-(Benzo\[*d*\]thiazol-2-yl)acetyl)-4-methylbenzenesulfonohydrazide (**3b**)^[@ref34]^ {#sec4.1.1.2}

It was obtained as colorless crystals; (EtOH), yield 85%, mp 185 °C; IR (KBr, cm^--1^) ν: 3427 (NH), 3164 (ArCH), 2993 (Aliph-H) 1692 (CO), 1547 (C=N), 1344, 1168 (O=S=O); ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 2.27 (s, 3H, CH~3~), 3.96 (s, 2H, CH~2~), 7.15 (d, *J* = 8 Hz, 2H, Ar-H), 7.44 (t, *J* = 8 Hz, 1H, benzothiazole-H), 7.52 (t, *J* = 8 Hz, 1H, benzothiazole-H), 7.63 (d, *J* = 8 Hz, 2H, Ar-H), 7.97 (d, *J* = 8 Hz, 1H, benzothiazole-H), 8.07 (d, *J* = 8 Hz, 1H, benzothiazole-H), 9.95 (s, 1H, NH), 10.52 (s, 1H, NH); ^13^C NMR (100 MHz, DMSO-*d*~6~): 21.4 (CH~3~), 39.1 (CH~2~), 122.4, 122.7, 125.5, 126.5, 128.1, 129.6, 130.3, 135.8, 143.7, 152.6, 164.6, 166.3 (Ar-C); Anal. Calcd for C~16~H~15~N~3~O~3~S~2~ (361.44): C %, 53.17; H %, 4.18; N %, 11.63. Found: C %, 53.19; H %, 4.22; N %, 11.61.

### 4.1.2. General Procedure for the Synthesis of **5a--d** {#sec4.1.2}

2-(Benzo\[*d*\]thiazol-2-yl)-3,3-bis(methylthio)acrylonitrile **4a** (0.01 mol) or ethyl 2-cyano-3,3-bis(methylthio)acrylate **4b** was added to a solution of *N*′-(2-(benzo\[*d*\]thiazol-2-yl)acetyl)arylsulfonohydrazides **3a,b** (0.01 mol) in dry DMF (30 mL) containing pulverized potassium hydroxide (0.01 mol). The reaction mixture was refluxed with stirring for 2 h (TLC monitoring). After cooling, the reaction mixture was poured into ice-cold water and neutralized with HCl. The solid product was filtered off, washed with water, and dried. It was further purified from hot ethyl acetate: petroleum ether (1:1). The precipitated solid was crystallized from DMF.

#### 4.1.2.1. *N*-(6-Amino-3-(benzo\[*d*\]thiazol-2-yl)-5-cyano-4-(methylthio)-2-oxopyridin-1(2*H*)-yl)benzenesulfonamide (**5a**) {#sec4.1.2.1}

It was obtained as a greenish yellow solid; (DMF), yield 78%, mp 300--301 °C; IR (KBr, cm^--1^): ν 3406, 3296 (NH, NH~2~), 3074 (ArCH), 2921 (Aliph-H), 2208 (CN), 1626 (CO), 1592 (C=N), 1367, 1132 (O=S=O); ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 2.46 (s, 3H, SCH~3~), 7.34--7.39 (m, 4H, 3Ar-H & benzothiazole-H), 7.45 (t, *J* = 8 Hz, 1H, benzothiazole-H), 7.50 (br, 2H, NH~2~), 7.73--7.76 (m, *J* = 8 Hz, 2H, Ar-H), 7.93 (d, *J* = 8 Hz, 1H, benzothiazole H), 8.99 (d, *J* = 8 Hz, 1H, benzothiazole H); ^13^C NMR (100 MHz, DMSO-*d*~6~): 25.9 (CH~3~), 117.8 (CN), 73.9, 110.7, 121.9, 122.5, 124.6, 126.0, 126.6, 127.5, 128.2, 129.6, 130.3, 135.8, 152.0, 157.9, 159.02, 162.8 (Ar-C); Anal. Calcd for C~20~H~15~N~5~O~3~S~3~ (469.56): C %, 51.16; H %, 3.22; N %, 14.91. Found: C %, 51.13; H %, 3.20; N %, 14.89.

#### 4.1.2.2. *N*-(6-Amino-3-(benzo\[*d*\]thiazol-2-yl)-5-cyano-4-(methylthio)-2-oxopyridin-1(2*H*)-yl)-4-methylbenzenesulfonamide (**5b**) {#sec4.1.2.2}

It was obtained as a greenish yellow solid; (DMF), yield 75%, mp 315--317 °C; IR (KBr, cm^--1^) ν: 3410, 3300 (NH, NH~2~), 3062 (ArCH), 2921 (Aliph-H), 2206 (CN), 1627 (CO), 1593 (C=N), 1435, 1132 (O=S=O); ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 2.31 (s, 3H, CH~3~), 2.45 (s, 3H, SCH~3~), 7.14 (d, *J* = 8 Hz, 2H, Ar-H), 7.37 (t, *J* = 8 Hz, 1H, benzothiazole-H), 7.46 (t, *J* = 8 Hz, 1H, benzothiazole-H), 7.49 (br, 2H, NH~2~), 7.62 (d, *J* = 8 Hz, 2H, Ar-H), 7.93 (d, *J* = 8 Hz, 1H, benzothiazole-H), 8.01 (d, *J* = 8 Hz, 1H, benzothiazole-H); ^13^C NMR (100 MHz, DMSO-*d*~6~): 19.7, 21.4 (CH~3~), 117.8 (CN), 73.9, 110.7, 121.9, 122.5, 124.6, 126.0, 126.6, 127.5, 128.2, 129.6, 130.3, 135.8, 152.0, 157.9, 159.0, 162.8 (Ar-C); Anal. Calcd for C~21~H~17~N~5~O~3~S~3~ (483.59): C %, 52.16; H %, 3.54; N %, 14.48. Found: C %, 52.12; H %, 3.51; N %, 14.46.

#### 4.1.2.3. *N*-(3-(Benzo\[*d*\]thiazol-2-yl)-5-cyano-6-hydroxy-4-(methylthio)-2-oxopyridin-1(2*H*)-yl)benzenesulfonamide (**5c**) {#sec4.1.2.3}

It was obtained as an army green solid; (acetone), yield 72%, mp 303--306 °C; IR (KBr, cm^--1^) ν: 3427 (OH), 3265 (NH), 3078 (ArCH), 2919 (Aliph-H), 2208 (CN), 1670 (CO), 1585 (C=N), 1340, 1163 (O=S=O); ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 2.59 (s, 3H, SCH~3~), 7.45 (t, *J* = 8 Hz, 1H, benzothiazole-H), 7.53--7.59 (m, 3H, Ar-H), 7.66 (t, *J* = 8 Hz, 1H, benzothiazole-H), 7.91 (d, *J* = 8 Hz, 2H, Ar-H), 8.07--8.09 (m, 2H, benzothiazole-H), 10.42 (s, 1H, NH); ^13^C NMR (100 MHz, DMSO-*d*~6~): 20.0 (CH~3~), 118.2 (CN), 101.0, 118.7, 122.5, 125.7, 127.5, 127.7, 127.8, 129.2, 129.6, 133.2, 141.7, 157.2, 159.9, 161.6, 165.9, 167.8 (Ar-C); Anal. Calcd for C~20~H~14~N~4~O~4~S~3~ (470.54): C %, 51.05; H %, 3.00; N %, 11.91. Found: C %, 51.02; H %, 3.03; N %,11.95.

#### 4.1.2.4. *N*-(3-(Benzo\[*d*\]thiazol-2-yl)-5-cyano-6-hydroxy-4-(methylthio)-2-oxopyridin-1(2*H*)-yl)-4-methylbenzenesulfonamide (**5d**) {#sec4.1.2.4}

It was obtained as an army green solid; (acetone), yield 70%, mp 277--278 °C; IR (KBr, cm^--1^) ν: 3431 (OH), 3295, (NH), 3071 (ArCH), 2923 (Aliph-H), 2210 (CN), 1671 (CO), 1589 (C=N), 1342, 1161 (O=S=O); ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 2.39 (s, 3H, CH~3~), 2.56 (s, 3H, SCH~3~), 7.36 (d, *J* = 8 Hz, 2H, Ar-H), 7.42 (t, *J* = 8 Hz, 1H, benzothiazole-H), 7.53 (t, *J* = 8 Hz, 1H, benzothiazole-H), 7.78 (d, *J* = 8 Hz, 2H, Ar-H), 8.03--8.07 (m, 2H, benzothiazole-H), 9.23 (br, 1H, OH), 10.22 (s, 1H, NH); ^13^C NMR (100 MHz, DMSO-*d*~6~): 19.7, 21.5 (SCH~3~), 118.2 (CN), 101.0, 118.8, 120.6, 122.2, 124.9, 127.9, 129.3, 130.3, 134.3, 145.0, 157.2, 160.0, 161.6, 165.9, 167.8 (Ar-C); Anal. calcd for C~21~H~16~N~4~O~4~S~3~ (484.57): C %, 52.05; H %, 3.33; N %, 11.56. Found: C %, 52.01; H %, 3.34; N %, 11.60.

### 4.1.3. General Procedure for the Synthesis of **9a--f** {#sec4.1.3}

N-Substituted bis(methylthiomethylene) (cyano)acetamide derivatives **6a--c** (0.01 mol) were added to *N*′-(2-(benzo\[*d*\]thiazol-2-yl)acetyl)arylsulfonohydrazides **3a,b** in dry dioxane (30 mL) containing pulverized potassium hydroxide (0.01 mol). The reaction mixture was refluxed until completion (TLC monitoring, 6--8 h). After cooling, the mixture was poured into ice water. The resulting solid was filtrated off, washed with water, and recrystallized from the appropriate solvent.

#### 4.1.3.1. 2-Amino-5-(benzo\[*d*\]thiazol-2-yl)-4-(methylthio)-6-oxo-*N*-phenyl-1-(phenylsulfonamido)-1,6-dihydropyridine-3-carboxamide (**9a**) {#sec4.1.3.1}

It was obtained as a greenish yellow solid; (acetone), yield 71%, mp 240--242 °C; IR (KBr, cm^--1^) ν: 3424, 3315 (NH, NH~2~), 3059 (ArCH), 2922 (Aliph-H), 1634 (CO), 1594 (C=N), 1321, 1162 (O=S=O); ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 2.24 (s, 3H, SCH~3~), 7.11 (t, *J* = 7.2 Hz, 1H, benzothiazole-H), 7.32--7.55 (m, 9H, 2NH~2~, 6Ar-H & benzothiazole-H), 7.76 (d, *J* = 7.2 Hz, 2H, Ar-H), 7.81 (d, *J* = 7.2 Hz, 2H, Ar-H), 7.88 (d, *J* = 8 Hz, 1H, benzothiazole-H), 7.97 (d, *J* = 8 Hz, 1H, benzothiazole-H); 10.40 (s, 1H, NH); Anal. Calcd for C~26~H~21~N~5~O~4~S~3~ (563.67): C %, 55.40; H %, 3.76; N %, 12.42. Found: C %, 55.45; H %, 3.78; N %, 12.46.

#### 4.1.3.2. 2-Amino-5-(benzo\[*d*\]thiazol-2-yl)-1-(4-methylphenylsulfonamido)-4-(methylthio)-6-oxo-*N*-phenyl-1,6-dihydropyridine-3-carboxamide (**9b**) {#sec4.1.3.2}

It was obtained as a greenish yellow solid; (acetone), yield 68%, mp 206--209 °C; IR (KBr, cm^--1^) ν: 3431, 3270 (NH, NH~2~), 3074 (ArCH), 2921 (Aliph-H), 1633 (CO), 1562 (C=N), 1367, 1175 (O=S=O); ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 2.24 (s, 3H, CH~3~), 2.34 (s, 3H, SCH~3~), 7.12 (t, *J* = 7.2 Hz, 1H, benzothiazole-H), 7.24 (t, *J* = 7.2 Hz, 1H, benzothiazole-H), 7.31--7.47 (m, 7H, NH~2~, 5Ar-H), 7.64 (d, *J* = 7.6 Hz, 2H, Ar-H), 7.69 (d, *J* = 7.6 Hz, 2H, Ar-H), 7.99 (d, *J* = 8 Hz, 1H, benzothiazole-H), 7.97 (d, *J* = 8 Hz, 1H, benzothiazole-H); 10.45 (s, 1H, NH), 11.21 (s, 1H, NH); Anal. Calcd for C~27~H~23~N~5~O~4~S~3~ (577.70): C %, 56.13; H %, 4.01; N %, 12.12. Found: C %, 56.19; H %, 4.05; N %, 12.18.

#### 4.1.3.3. 2-Amino-5-(benzo\[*d*\]thiazol-2-yl)-4-(methylthio)-6-oxo-1-(phenylsulfonamido)-*N*-(*p*-tolyl)-1,6-dihydropyridine-3-carboxamide (**9c**) {#sec4.1.3.3}

It was obtained as a beige solid; (acetone), yield 74%, mp 240--242 °C; 3429, 3268 (NH, NH~2~), 3076 (ArCH), 2962 (Aliph-H), 1657 (CO), 1387, 1168 (O=S=O); ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 2.31 (s, 3H, CH~3~), 2.50 (s, 3H, SCH~3~), 7.21 (d, *J* = 7.6 Hz, 2H, Ar-H), 7.51 (d, *J* = 7.6 Hz, 2H, Ar-H), 7.59 (t, *J* = 7.6 Hz, 1H, benzothiazole H), 7.73--7.76 (m, 3H, Ar-H), 7.74 (t, *J* = 7.6 Hz, 1H, benzothiazole H), 8.01 (d, *J* = 8 Hz, 2H, Ar-H), 8.20 (d, *J* = 8 Hz, 1H, benzothiazole-H), 8.46 (d, *J* = 8 Hz, 1H, benzothiazole-H), 9.28 (br, 2H, NH~2~), 11.17 (s, 1H, NH); Anal. Calcd for C~27~H~23~N~5~O~4~S~3~ (577.70): C %, 56.13; H %, 4.01; N %, 12.12. Found: C %, 56.15; H %, 4.02; N %, 12.13.

#### 4.1.3.4. 2-Amino-5-(benzo\[*d*\]thiazol-2-yl)-1-(4-methylphenylsulfonamido)-4-(methylthio)-6-oxo-*N*-(*p*-tolyl)-1,6-dihydropyridine-3-carboxamide (**9d**) {#sec4.1.3.4}

It was obtained as a greenish yellow solid; (acetone), yield 72%, mp 209--210 °C; IR (KBr, cm^--1^) ν: 3420, 3311 (NH, NH~2~), 3059 (ArCH), 2919 (Aliph-H), 1642 (CO), 1590 (C=N), 1344, 1160 (O=S=O); ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 2.23 (s, 3H, CH~3~), 2.28 (s, 3H, CH~3~), 2.36 (s, 3H, SCH~3~), 7.18 (d, *J* = 7.6 Hz, 2H, Ar-H), 7.36--7.38 (m, 3H, 2Ar-H & benzothiazole-H), 7.43--7.47 (m, 3H, 2Ar-H & benzothiazole-H), 7.63 (d, *J* = 7.6 Hz, 2H, Ar-H), 7.69 (d, *J* = 7.6 Hz, 2H, Ar-H), 7.90 (d, *J* = 8 Hz, 1H, benzothiazole-H), 8.00 (d, *J* = 8 Hz, 1H, benzothiazole-H), 10.36 (s, 1H, NH), 11.32 (s, 1H, NH); Anal. Calcd for C~28~H~25~N~5~O~4~S~3~ (591.72): C %, 56.83; H %, 4.26; N %, 11.84. Found: C %, 56.84; H %, 4.27; N %, 11.81.

#### 4.1.3.5. 2-Amino-5-(benzo\[*d*\]thiazol-2-yl)-*N*-(4-methoxyphenyl)-4-(methylthio)-6-oxo-1-(phenylsulfonamido)-1,6-dihydropyridine-3-carboxamide (**9e**) {#sec4.1.3.5}

It was obtained as a beige solid; (dioxane), yield 77%, mp 249--250 °C; IR (KBr, cm^--1^) ν: 3429, 3316 (NH, NH~2~), 3057 (ArCH), 2920 (Aliph-H), 1656 (CO), 1596 (C=N), 1353, 1163 (O=S=O); ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 2.25 (s, 3H, SCH~3~), 3.76 (s, 3H, OCH~3~), 6.96 (d, *J* = 8 Hz, 2H, Ar-H), 7.35 (t, *J* = 7.6 Hz, 1H, benzothiazole-H), 7.45 (t, *J* = 7.6 Hz, 1H, benzothiazole-H), 7.50 (br, 2H, NH~2~), 7.55--7.60 (m, 2H, Ar-H), 7.67--7.70 (m, 3H, Ar-H), 7.82 (d, *J* = 8 Hz, 2H, Ar-H), 7.90 (d, *J* = 8 Hz, 1H, benzothiazole-H), 7.98 (d, *J* = 8 Hz, 1H, benzothiazole-H), 10.35 (s, 1H, NH), 11.46 (s, 1H, NH); Anal. Calcd for C~27~H~23~N~5~O~5~S~3~ (593.70): C %, 54.62; H %, 3.90; N %, 11.80. Found: C %, 54.66; H %, 3.92; N %, 11.72.

#### 4.1.3.6. 2-Amino-5-(benzo\[*d*\]thiazol-2-yl)-*N*-(4-methoxyphenyl)-1-(4-methylphenylsulfonamido)-4-(methylthio)-6-oxo-1,6-dihydropyridine-3-carboxamide (**9f**) {#sec4.1.3.6}

It was obtained as a greenish yellow solid; (MeOH), yield 76%, mp 250--252 °C; IR (KBr, cm^--1^) ν: 3413, 3399 (NH, NH~2~), 3054 (ArCH), 2921 (Aliph-H), 1630 (CO), 1567 (C=N), 1466, 1172 (O=S=O); ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 2.22 (s, 3H, CH~3~), 2.33 (s, 3H, SCH~3~), 3.76 (s, 3H, OCH~3~), 6.94 (d, *J* = 8 Hz, 2H, Ar-H), 7.13--7.18 (m, 4H, 2Ar-H & NH~2~), 7.31 (t, *J* = 7.6 Hz, 1H, benzothiazole-H), 7.41 (t, *J* = 7.6 Hz, 1H, benzothiazole-H), 7.67--7.70 (m, 4H, Ar-H), 7.86 (d, *J* = 8 Hz, 1H, benzothiazole-H), 7.97 (d, *J* = 8 Hz, 1H, benzothiazole-H), 10.15 (s, 1H, NH); ^13^C NMR (100 MHz, DMSO-*d*~6~): δ 19.6 (CH~3~), 21.4 (SCH~3~), 55.1 (OCH~3~), 97.6, 108.6, 114.3, 121.4, 121.6, 121.7, 124.1, 125.6, 125.8, 128.4, 133.1, 135.5, 139.0, 150.8, 151.9, 154.0, 155.8, 159.3, 164.2, 166.0 (Ar-C); Anal. Calcd for C~28~H~25~N~5~O~5~S~3~ (607.72): C %, 57.34; H %, 4.15; N %, 11.52; S %, 15.83. Found: C %, 57.32; H %, 4.13; N %, 11.50; S %, 15.84.

### 4.1.4. General Procedure for the Synthesis of **11a,b** {#sec4.1.4}

A mixture of **5a,b** (0.01 mol) and hydrazine hydrate (0.02 mol) in a mixture of methanol/DMF (50:50 vol %) containing three drops of piperidine was heated under reflux for 2 h (TLC monitoring). The mixture was then concentrated under reduced pressure to afford a solid residue that was triturated with ethanol, filtered off, and washed with ethanol. The solid product was recrystallized from methanol.

#### 4.1.4.1. *N*-(3,4-Diamino-7-(benzo\[*d*\]thiazol-2-yl)-6-oxo-1*H*-pyrazolo\[4,3-*c*\]pyridin-5(6*H*)-yl)benzenesulfonamide (**11a**) {#sec4.1.4.1}

It was obtained as a pale yellow solid; (MeOH), yield 68%, mp 309--310 °C; IR (KBr, cm^--1^) ν: 3396, 3297 (NH, NH~2~), 3065 (ArCH), 1661 (CO), 1603 (C=N), 1321, 1137 (O=S=O); ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 5.58 (br, 2H, NH~2~), 7.13 (t, *J* = 7.6 Hz, 1H, benzothiazole-H), 7.33 (t, *J* = 7.6 Hz, 1H, benzothiazole-H), 7.33--7.39 (m, 3H, Ar-H), 7.56 (br, 2H, NH~2~), 7.80--7.86 (m, 4H, 2Ar-H & 2benzothiazole-H), 10.86 (s, 1H, NH); ^13^C NMR (100 MHz, DMSO-*d*~6~): δ 86.3, 119.9, 121.4, 121.9, 125.4, 126.6, 128.0, 129.7, 133.2, 144.1, 148.5, 150.8, 151.7, 153.2, 159.6, 162.8, 165.0 (Ar-C); Anal. Calcd. for C~19~H~15~N~7~O~3~S~2~ (453.50): C %, 50.32; H %, 3.33; N %, 21.62. Found: C %, 50.33; H %, 3.32; N %, 21.63.

#### 4.1.4.2. *N*-(3,4-Diamino-7-(benzo\[*d*\]thiazol-2-yl)-6-oxo-1*H*-pyrazolo\[4,3-*c*\]pyridin-5(6*H*)-yl)-4-methylbenzenesulfonamide (**11b**) {#sec4.1.4.2}

It was obtained as a pale yellow solid; (MeOH), yield 62%, mp 310--312 °C; IR (KBr, cm^--1^) ν: 3395, 3330 (NH, NH~2~), 3063 (ArCH), 2922 (Aliph-H), 1644 (CO), 1605 (C=N), 1321, 1131 (O=S=O); ^1^H NMR (400 MHz, DMSO-*d*~6~): δ 2.35 (s, 3H, CH~3~), 5.59 (br, 2H, NH~2~), 7.14 (t, *J* = 8 Hz, 1H, benzothiazole-H), 7.19 (d, *J* = 8 Hz, 2H, Ar-H), 7.33 (t, *J* = 8 Hz, 1H, benzothiazole-H), 7.51 (br, 2H, NH~2~), 7.70 (d, *J* = 8 Hz, 2H, Ar-H), 7.82 (d, *J* = 8 Hz, 1H, benzothiazole-H), 7.85 (d, *J* = 8 Hz, 1H, benzothiazole-H), 11.37 (s, 1H, NH); ^13^C NMR (100 MHz, DMSO-*d*~6~): δ 21.6 (CH~3~), 81.4, 120.1, 121.5, 123.2, 126.1, 126.2, 129.9, 135.0, 144.4, 151.4, 152.0, 156.0, 162.0, 164.3 (Ar-C); Anal. Calcd for C~20~H~17~N~7~O~3~S~2~ (467.52): C %, 51.38; H %, 3.67; N %, 20.97. Found: C %, 51.39; H %, 3.67; N %, 20.99.

4.2. Antimicrobial Activity {#sec4.2}
---------------------------

Antimicrobial assessment and the MIC performed at the Microbiology Unit in Biochemistry Central Lab, Faculty of Science, Cairo University, Cairo, Egypt. Chemical compounds were individually tested against a panel of Gram positive and Gram-negative bacterial pathogens and the fungi utilizing agar well diffusion method.^[@ref39]^ The compounds were tested at a concentration of 15 mg/mL against both bacterial and fungal strains. Microbial suspension was prepared in sterilized saline equivalent to McFarland 0.5 standard solution (1.5 × 10^5^ cfu mL^--1^), and its turbidity was adjusted to the optical density (OD) = 0.13 using a spectrophotometer at 625 nm. Optimally, within 15 min after adjusting the turbidity of the inoculum suspension, a sterile cotton swab was dipped into the adjusted suspension, was flooded on the dried agar surface and then allowed to dry for 15 min with lid in place. Wells of 6 mm diameter was made in the solidified media with the help of sterile borer. The solution of the tested compound (100 μL) was added to each well with the help of micropipette. The plates were incubated at 37 °C. The zone of inhibition (mm) was measured after 24 h incubation at 30 °C in the case of bacterial plates and 48 h in the case fugal plates. This experiment was carried out in triplicate, diameters of the inhibition zones were measured in millimeters, and the results were recorded for each tested compound as % inhibition ± SD.

4.3. MIC Measurement {#sec4.3}
--------------------

Stock solutions of the tested compounds, Ampicillin, Gentamicin, and Nystatin were prepared in DMSO at a concentration of 1000 μg/mL followed by serial twofold dilution at concentrations of (500, 250,125, 62.5, and 31.25 μg/mL). Each concentration was mixed with sterile nutrient agar (Sigma-Aldrich, USA) in a sterile plate followed by the inoculation of a defined microbial inoculum onto the agar plate surface. The plates were incubated at 37 °C in a humid chamber, and MIC endpoints were read after 24 h. The MIC end point is recorded as the lowest concentration of the antimicrobial agent that completely inhibits growth under suitable incubation conditions.

4.4. Cytotoxicity Effect {#sec4.4}
------------------------

The toxicity effect tests were performed at the Tissue Culture Unit, the Egyptian Company for Production of Vaccines, Sera and Drugs (VACSERA), Giza, Egypt. The toxicity effect on human dermal cell line (HFB4) was studied for the most active compounds by using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Potential cytotoxicity of the compounds was tested as follows: cells were plated in 96 multi-well plates (10^4^ cells/well) for 24 h before treatment with the compound(s) to allow attachment to the wall of the plate. Different concentrations of the compounds (0, 6.25, 12.5, 25, 50, and 100 μg/mL) added to the cell monolayer triplicate wells were prepared for each individual dose. Monolayer cells were incubated with the compound(s) for 48 h at 37 °C. Subsequently, an amount of 20 μL of MTT solution was added to the wells and incubated for 4 h. DMSO (200 μL) was added to each wall for dissolving the formed dark blue formazan crystals. Their OD of visible cells was detected using a spectrophotometer. In order to determine the cell viability for the tested compounds, OD of each tested compound was compared with OD of untreated control.

4.5. Enzyme Assay {#sec4.5}
-----------------

Enzyme assay experiments were carried out at the Tissue Culture Unit, the Egyptian Company for Production of Vaccines, Sera and Drugs (VACSERA), Giza, Egypt.

### 4.5.1. DHPS Assay {#sec4.5.1}

DHPS activity was determined by bacterial-DHPS catalytic assay. The reaction mixture consisted of 5 mM magnesium chloride (MgCl~2~), 40 mM Tris-HCl (pH 8.2), 1 μM radiolabeled *p*-amino benzoic acid \[^3^H\]pABA, 10 mM dithiothreitol (DTT), and 10 μM 6-hydroxymethyl-7,8-dihydropterin pyrophosphate (H~2~PtCH~2~OPP) in a total volume of 100 μL. Stock solutions of the tested compounds were prepared by dissolving each tested compounds in DMSO, 100 μg/mL. The reaction was initiated via adding 100 μL of DHPS-containing lysates (containing 0.5 mU of enzyme) at 37 °C. Reaction mixtures without lysate or H~2~PtCH~2~OPP served as blanks. After 30 min incubation, the reactions were terminated by placing the reaction tubes on ice, and then, 100 μL of the reaction volume was spotted onto 3 × 30 cm strips of 3MM chromatography paper (Whatman Laboratory Products Inc.). The strips were developed in a descending chromatography tank utilizing 0.1 M KH~2~PO~4~, pH 7.0, as an elution buffer. Under such conditions, unreacted \[^3^H\]PABA migrates with the solvent front and radiolabeled product, 7,8-dihydropteroate (DHF, H~2~Pte), remains at the origin. The origins that contain the labeled products of the reaction were cut from the strips and placed in scintillation vials. The radioactive activity of the labeled products was measured by counting the resultant photon emission in a liquid scintillation counter (Packard Tri-Carb; Packard Instrument Co. Inc., Downers Grove) 24 h after the addition of 9.5 mL of counting cocktail (3A70b; Research Products International Corp., Mt. Prospect). Results were expressed as the mean and standard deviation of triplicate samples in picomoles of product formed per milligram of total protein.

### 4.5.2. DHFR Assay {#sec4.5.2}

DHFR inhibitor screening kit (BioVision, Catalog \#K247-100) was used for this assay. The assay for the inhibitory effect of target compounds against DHFR enzyme was applied as indicated in the DHFR assay kit. DHFR provided with the kit is human DHFR recombinant expressed in *E. coli*. Stock solutions of the tested compounds with different concentrations were prepared by dissolving each tested compounds to 100× in DMSO. Different concentrations (2 μL) of the tested compounds were added into wells of 96-well clear plate. Stock solutions of the DHFR were prepared by adding 2 μL of DHFR to 798 μL of supplied DHFR assay buffer. An amount of 98 μL of diluted DHFR was added into the wells containing the tested samples and enzyme control. An amount of 40 μL of diluted NADPH (10 μL of NADPH in 390 μL DHFR assay buffer) was also added to the aforementioned wells and then mixed well by using vortex. After incubation at room temperature for 10--15 min without exposing to light, 60 μL of diluted DHFR substrate (40 μL of DHFR stock substrate in 560 μL DHFR assay buffer) was added to each well in 96-well plate that contains the test samples and enzyme control and mixed well. Consequently, the total volume is 200 μL. Absorbance was immediately measured at 340 nm in kinetic mode for 10--20 min at room temperature using ELISA reader. The relationship between absorbance with time was plotted, and the slope for all test inhibitor samples was calculated. The percentages of both of relative inhibition and relative activity were determined using [eqs [1](#eq1){ref-type="disp-formula"}](#eq1){ref-type="disp-formula"} and [2](#eq2){ref-type="disp-formula"}, respectively.where, S is sample screening and EC is enzyme control.

4.6. Statistical Analysis {#sec4.6}
-------------------------

The experiments was repeated three times, and all data were expressed as mean ± SD. Significant difference was tested via applying Student's test between two groups to the data. Such statistical analyses was carried out using GraphPad Prism Software version 6 (\**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, and \*\*\*\**p* \< 0.0001).

4.7. Molecular Docking {#sec4.7}
----------------------

The molecular studies were carried out using Molecular Operating Environment (MOE 2014) All the minimizations were performed with MOE until a rmsd gradient of 0.01 kcal/mol Å with MMFF94X force field, and the partial charges were automatically calculated. Docking simulations were performed using the crystal structure of DHPS enzyme (PDB ID: 3TYE) in complex to XTZ and the crystal structure of DHFR enzyme (PDB ID: 3FRB) in complex to TOP which was obtained from Protein Data Bank. Enzyme structures were checked for missing atoms, bonds, and contacts. Water molecules and bound ligands were removed. Protonate 3D application of MOE was used to add the missing hydrogens and properly assign the ionization states. The ligand molecules were constructed using the builder molecule and were energy minimized. The active site was generated using the MOE-Alpha site finder. Dummy atoms were created from the obtained alpha spheres. Ligands were docked within the active sites using the MOE-Dock. The generated poses were energy minimized using the MMFF94x force field. Finally, the optimized poses were ranked using the GBVI/WSA DG free-energy estimates. Docking poses were visually inspected, and interactions with binding pocket residues were analyzed.

The Supporting Information is available free of charge at [https://pubs.acs.org/doi/10.1021/acsomega.0c00280](https://pubs.acs.org/doi/10.1021/acsomega.0c00280?goto=supporting-info).All spectral analysis such as IR, ^1^H NMR, and ^13^C NMR spectra for the newly synthesized compounds ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c00280/suppl_file/ao0c00280_si_001.pdf))
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